Organ preservation in rectal cancer – Challenges and future strategies

[1]  H. Lenz,et al.  Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713 , 2017, Clinical colorectal cancer.

[2]  L. Stassen,et al.  Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer. , 2016, Journal of the National Cancer Institute.

[3]  E. Cotte,et al.  Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Fuller,et al.  The MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development , 2016, Front. Oncol..

[5]  D. Tait,et al.  Results of a prospective randomised control 6 vs 12 trial: Is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy? , 2016 .

[6]  Gina Brown,et al.  Magnetic Resonance Tumor Regression Grade and Residual Mucosal Abnormality as Predictors for Pathological Complete Response in Rectal Cancer Postneoadjuvant Chemoradiotherapy , 2016, Diseases of the colon and rectum.

[7]  H. Zhang,et al.  Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Rödel,et al.  Targeted agents in GI radiotherapy: Clinical efficacy and side effects. , 2016, Best practice & research. Clinical gastroenterology.

[9]  Young Bae Kim,et al.  Clinical Significance of the Endoscopic Finding in Predicting Complete Tumor Response to Preoperative Chemoradiation Therapy in Rectal Cancer , 2016, World Journal of Surgery.

[10]  Zhi-rui Zhou,et al.  Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: An updated systematic review and meta-analysis , 2016, Oncotarget.

[11]  L. Boni,et al.  Final results of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer. , 2016 .

[12]  T. Niu,et al.  Rectal Cancer: Assessment of Neoadjuvant Chemoradiation Outcome based on Radiomics of Multiparametric MRI , 2016, Clinical Cancer Research.

[13]  B. Ganeshan,et al.  Performance of diffusion-weighted imaging, perfusion imaging, and texture analysis in predicting tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3T MR: initial experience , 2016, Abdominal Radiology.

[14]  M. Berger,et al.  KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy , 2016, Annals of Surgical Oncology.

[15]  S. Barni,et al.  Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies , 2016, Annals of surgery.

[16]  T. Conroy,et al.  ACCORD12/0405-Prodige 2 phase III trial neoadjuvant treatment in rectal cancer: Results after 5 years of follow-up. , 2016 .

[17]  Richard Emsley,et al.  Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. , 2016, The Lancet. Oncology.

[18]  D. Zips,et al.  Long-term local control and survival after preoperative radiochemotherapy in combination with deep regional hyperthermia in locally advanced rectal cancer. , 2016 .

[19]  Jian Wang,et al.  Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: a 3-year follow-up study. , 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[20]  R. Beart,et al.  Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. , 2015, Journal of the National Cancer Institute.

[21]  Angelita Habr-Gama,et al.  The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation , 2015, Oncotarget.

[22]  M. Baumann,et al.  Residual γH2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  Shao Hui Huang,et al.  External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma , 2015, Acta oncologica.

[24]  H. Harling,et al.  High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. , 2015, The Lancet. Oncology.

[25]  T. Hothorn,et al.  Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. , 2015, The Lancet. Oncology.

[26]  David D. Smith,et al.  Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. , 2015, The Lancet. Oncology.

[27]  R. Salazar,et al.  A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features , 2015, BMC Cancer.

[28]  K. Otomo,et al.  Analysis of motion of the rectum during preoperative intensity modulated radiation therapy for rectal cancer using cone-beam computed tomography , 2015, Radiation oncology.

[29]  M. Kreis,et al.  Use of Preoperative Magnetic Resonance Imaging to Select Patients with Rectal Cancer for Neoadjuvant Chemoradiation—Interim Analysis of the German OCUM Trial (NCT01325649) , 2015, Journal of Gastrointestinal Surgery.

[30]  S. Marnitz,et al.  Comparative treatment planning study on sequential vs. simultaneous integrated boost in head and neck cancer patients , 2015, Strahlentherapie und Onkologie.

[31]  X. An,et al.  Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial. , 2014, International journal of radiation oncology, biology, physics.

[32]  Karin Haustermans,et al.  The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  Andre Dekker,et al.  Nomogram predicting response after chemoradiotherapy in rectal cancer using sequential PETCT imaging: a multicentric prospective study with external validation. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[34]  H. Verkooijen,et al.  Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[35]  T. Holm,et al.  Local control and survival after extralevator abdominoperineal excision for locally advanced or low rectal cancer , 2014, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[36]  N. Petrelli,et al.  Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  K. Haustermans,et al.  PG 6.2 Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: disease free survival results at interim analysis , 2014 .

[38]  J. Stoker,et al.  Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. , 2013, Radiology.

[39]  C. Willett,et al.  Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. , 2013, International journal of radiation oncology, biology, physics.

[40]  C. Buskens,et al.  Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer , 2013, British Journal of Surgery.

[41]  Xi Lin,et al.  Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis. , 2013, European journal of cancer.

[42]  I. Vogelius,et al.  Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. , 2013, International journal of radiation oncology, biology, physics.

[43]  M. Weinmann,et al.  Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone , 2012, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[44]  D. Tait,et al.  Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Patrick Granton,et al.  Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.

[46]  K. Pantel,et al.  Circulating tumor cells and circulating tumor DNA. , 2012, Annual review of medicine.

[47]  Geerard L Beets,et al.  Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  N. Petrelli,et al.  Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Gina Brown,et al.  Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  L. Boni,et al.  Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[52]  E. Urso,et al.  Circulating Cell-Free DNA: A Promising Marker of Pathologic Tumor Response in Rectal Cancer Patients Receiving Preoperative Chemoradiotherapy , 2011, Annals of Surgical Oncology.

[53]  J. Fleshman,et al.  Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  J. Gama-Rodrigues,et al.  Complete Clinical Response After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer: Characterization of Clinical and Endoscopic Findings for Standardization , 2010, Diseases of the colon and rectum.

[55]  T. Beißbarth,et al.  Failure of Downregulation of Survivin Following Neoadjuvant Radiochemotherapy in Rectal Cancer Is Associated with Distant Metastases and Shortened Survival , 2010, Clinical Cancer Research.

[56]  L. Ellis,et al.  Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. , 2010, International journal of radiation oncology, biology, physics.

[57]  M. Genna,et al.  Regional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum , 2010, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[58]  Frederik Maes,et al.  Biological image-guided radiotherapy in rectal cancer: challenges and pitfalls. , 2009, International journal of radiation oncology, biology, physics.

[59]  B. Beuthien-Baumann,et al.  Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by γH2AX staining , 2009, International journal of radiation biology.

[60]  V. Fazio,et al.  Predictive Factors of Pathologic Complete Response After Neoadjuvant Chemoradiation for Rectal Cancer , 2009, Annals of surgery.

[61]  P. Lambin,et al.  Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer. , 2009, The Cochrane database of systematic reviews.

[62]  H. McLeod,et al.  Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. , 2009, International journal of radiation oncology, biology, physics.

[63]  Yves Pommier,et al.  γH2AX and cancer , 2008, Nature Reviews Cancer.

[64]  A. Gingras,et al.  PP4 is a γH2AX phosphatase required for recovery from the DNA damage checkpoint , 2008, EMBO reports.

[65]  A. Figer,et al.  An Interval >7 Weeks between Neoadjuvant Therapy and Surgery Improves Pathologic Complete Response and Disease–Free Survival in Patients with Locally Advanced Rectal Cancer , 2008, Annals of Surgical Oncology.

[66]  P. Delrio,et al.  Changes in FDG uptake during preoperative radiochemotherapy predict prognosis in patients with locally advanced rectal cancer (LARC) , 2007 .

[67]  V. Valentini,et al.  Functional results after radiochemotherapy and total mesorectal excision for rectal cancer , 2007, International Journal of Colorectal Disease.

[68]  J. Gama-Rodrigues,et al.  Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy , 2006, Journal of Gastrointestinal Surgery.

[69]  Bernard Leduc,et al.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  P. Olive,et al.  Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[71]  D. Durocher,et al.  γH2AX as a Checkpoint Maintenance Signal , 2006 .

[72]  J. Lieberman,et al.  A phosphatase complex that dephosphorylates γH2AX regulates DNA damage checkpoint recovery , 2006, Nature.

[73]  D. Durocher,et al.  gammaH2AX as a checkpoint maintenance signal. , 2006, Cell cycle.

[74]  J. Lieberman,et al.  γ-H2AX Dephosphorylation by Protein Phosphatase 2A Facilitates DNA Double-Strand Break Repair , 2005 .

[75]  L. Cerezo,et al.  The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[76]  J. Lieberman,et al.  gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. , 2005, Molecular cell.

[77]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[78]  Fábio Guilherme Campos,et al.  Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy: Long-term Results , 2004, Annals of surgery.

[79]  P. Schlag,et al.  Stellenwert der Hyperthermie für die chirurgische Onkologie , 2002 .

[80]  E. Rogakou,et al.  Quantitative Detection of 125IdU-Induced DNA Double-Strand Breaks with γ-H2AX Antibody , 2002 .

[81]  E. Rogakou,et al.  Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody. , 2002, Radiation research.

[82]  P. Adeleine,et al.  Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  S. Andreola,et al.  Pathological features of rectal cancer after preoperative radiochemotherapy , 1998, International Journal of Colorectal Disease.

[84]  R. Heald.  The ‘Holy Plane’ of Rectal Surgery , 1988, Journal of the Royal Society of Medicine.

[85]  W. Mendenhall,et al.  Patterns of Recurrence in Adenocarcinoma of the Rectum and Rectosigmoid Treated with Surgery Alone , 1982, International journal of radiation oncology, biology, physics.